Celloram

Celloram is a private, preclinical-stage biotech founded in 2018 with a focus on small molecules and cell therapies for oncology, autoimmune, and metabolic diseases. The company has raised $9M in total funding from investors including MedPacto and Theragen Etex and is led by a seasoned team with deep expertise in cancer research and drug development. Its strategy centers on a dual-platform approach: developing novel small molecule inhibitors and dendritic cell-based immunotherapies designed to stimulate self-healing and enhance therapeutic efficacy. Celloram operates from its headquarters in Cleveland's University Circle, leveraging its academic connections for research and development.

Dual-platform approach focusing on 1) dendritic cell-based cellular immunotherapies to stimulate self-healing, and 2) novel small molecule inhibitors as targeted therapies. Core concepts include modulating tissue microenvironments and restoring cellular homeostasis.

Celloram operates in highly competitive fields. In cellular immunotherapy, it faces numerous companies developing dendritic cell and other antigen-presenting cell therapies. In targeted small molecule inhibitors, the landscape is even more crowded across oncology and immunology. Differentiation will require demonstrating superior efficacy, safety, or novel mechanisms of action in its preclinical models.